BioGend Therapeutics Co (ROCO:6733) EBIT: NT$-103.5 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6733 BioGend Therapeutics Co Ltd ROCO:6733
73 GF Score
Price NT$25.35
GF Value NT$70.22
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is BioGend Therapeutics Co EBIT?

BioGend Therapeutics Co ROCO:6733 -2.50% 73 EBIT is NT$-103.5 Mil as of Dec. 2025. GuruFocus rates ROCO:6733 with a GF Score™ of 73/100 and a GF Value™ of NT$70.22 (Significantly Undervalued). The stock has 1 warning sign investors should review.

BioGend Therapeutics Co's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2025 was NT$-25.8 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-103.5 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. BioGend Therapeutics Co's annualized ROC % for the quarter that ended in Dec. 2025 was -39.00%. BioGend Therapeutics Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -79.61%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. BioGend Therapeutics Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -3.45%.

BioGend Therapeutics Co  (ROCO:6733) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

BioGend Therapeutics Co's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-114.572 * ( 1 - 7.8% )/( (276.375 + 265.38)/ 2 )
=-105.635384/270.8775
=-39.00 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=838.533 - 30.955 - ( 531.203 - max(0, 34.714 - 650.656+531.203))
=276.375

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=815.378 - 32.097 - ( 517.901 - max(0, 36.163 - 636.43+517.901))
=265.38

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

BioGend Therapeutics Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-103.084/( ( (43.129 + max(87.989, 0)) + (43.111 + max(84.749, 0)) )/ 2 )
=-103.084/( ( 131.118 + 127.86 )/ 2 )
=-103.084/129.489
=-79.61 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(59.382 + 19.326 + 40.698) - (30.955 + 0 + 0.462)
=87.989

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(58.957 + 20.519 + 37.709) - (32.097 + 0 + 0.339)
=84.749

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

BioGend Therapeutics Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-103.459/2996.437
=-3.45 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioGend Therapeutics Co EBIT Related Terms

BioGend Therapeutics Co EBIT Historical Data

* Premium members only.

The historical data trend for BioGend Therapeutics Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioGend Therapeutics Co EBIT Chart

BioGend Therapeutics Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -144.25 -213.80 -168.96 -128.03 -103.46

BioGend Therapeutics Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -32.92 -38.43 -28.05 -11.21 -25.77

ROCO:6733 vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, BioGend Therapeutics Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioGend Therapeutics Co EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioGend Therapeutics Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where BioGend Therapeutics Co's EV-to-EBIT falls into.


ROCO:6733
73GF Score
BioGend Therapeutics Co Ltd ROCO:6733
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioGend Therapeutics Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-103.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of NT$-103.5 Mil mean?
BioGend Therapeutics Co (ROCO:6733) has a EBIT of NT$-103.5 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on BioGend Therapeutics Co.
Is BioGend Therapeutics Co's EBIT too high?
BioGend Therapeutics Co's current EBIT is NT$-103.5 Mil. Overall, BioGend Therapeutics Co has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioGend Therapeutics Co's EBIT compare to VRTX and REGN?
BioGend Therapeutics Co's EBIT of NT$-103.5 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on BioGend Therapeutics Co. BioGend Therapeutics Co's current EBIT is NT$-103.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGend Therapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, BioGend Therapeutics Co (ROCO:6733) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$70.22, compared to a current price of NT$25.35 — trading 63.9% below its estimated fair value. The current EBIT is NT$-103.5 Mil. BioGend Therapeutics Co's overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For BioGend Therapeutics Co (ROCO:6733), the current EBIT is NT$-103.5 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioGend Therapeutics Co (ROCO:6733) Overvalued in 2026?

Based on GuruFocus' analysis, BioGend Therapeutics Co stock appears to be undervalued. The current stock price of NT$25.35 is trading 63.9% below its estimated GF Value™ of NT$70.22. GuruFocus considers BioGend Therapeutics Co to be Significantly Undervalued.

Key valuation signals for ROCO:6733:

  • EBIT: NT$-103.5 Mil
  • GF Value™: NT$70.22 vs. price of NT$25.35 (63.9% below fair value)
  • GF Score™: 73/100 with 1 warning sign

No single metric tells the full story. See the ROCO:6733 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioGend Therapeutics Co Business Description

Address Park Street, 4th Floor, No. 3-2, Nangang District, Taipei, TWN, 115
BioGend Therapeutics Co Ltd is a Taiwan-based company involved in the research and development of orthopedic medical equipment and related products, and the sale of related products. It is involved in the research and development of inventive cartilage repair technology and products, adipose stem cell extraction technology, and others. Geographically, the company generates a majority of its revenue from Taiwan, followed by China, Malaysia, and other regions.
73GF Score

Get the complete analysis for ROCO:6733

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$25.35
Price
NT$70.22
GF Value